Financial reports
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
ARS
2022 FY
Annual report to shareholders
11 Jul 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2021 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
26 Mar 24
8-K
Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million
12 Mar 24
8-K
Other Events
6 Feb 24
8-K
Results of Operations and Financial Condition
2 Feb 24
8-K
Entry into a Material Definitive Agreement
26 Jan 24
8-K
Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024
4 Jan 24
8-K
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
9 Nov 23
8-K
Other Events
16 Oct 23
8-K
Other Events
13 Oct 23
8-K
Other Events
11 Sep 23
Registration and prospectus
424B3
Prospectus supplement
9 Feb 24
424B3
Prospectus supplement
5 Feb 24
S-3
Shelf registration
26 Jan 24
S-8
Registration of securities for employees
9 Nov 23
424B5
Prospectus supplement for primary offering
24 Feb 23
424B5
Prospectus supplement for primary offering
22 Feb 23
S-8
Registration of securities for employees
15 Dec 22
424B5
Prospectus supplement for primary offering
2 Sep 22
S-8
Registration of securities for employees
3 Jun 22
S-8
Registration of securities for employees
9 Nov 21
Proxies
DEF 14A
Definitive proxy
11 Jul 23
DEF 14A
Definitive proxy
26 Oct 22
PRE 14A
Preliminary proxy
11 Oct 22
DEF 14A
Definitive proxy
10 Jun 22
PRE 14A
Preliminary proxy
27 May 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
29 Apr 20
DEF 14A
Definitive proxy
29 Apr 20
Other
EFFECT
Notice of effectiveness
5 Feb 24
CORRESP
Correspondence with SEC
31 Jan 24
UPLOAD
Letter from SEC
30 Jan 24
EFFECT
Notice of effectiveness
1 Dec 20
CORRESP
Correspondence with SEC
25 Nov 20
UPLOAD
Letter from SEC
18 Nov 20
EFFECT
Notice of effectiveness
3 Oct 19
CERT
Certification of approval for exchange listing
2 Oct 19
CORRESP
Correspondence with SEC
30 Sep 19
CORRESP
Correspondence with SEC
30 Sep 19
Ownership
4
John P. Hamill
14 Mar 24
4
Bernd R. Seizinger
14 Mar 24
4
JOHN B HENNEMAN III
14 Mar 24
4
Oren Gilad
14 Mar 24
SC 13G
Sio Capital Management, LLC
14 Feb 24
SC 13G/A
HIRSCHMAN ORIN
7 Feb 24
4
Rifat Pamukcu
24 Aug 23
4
Michael Grissinger
24 Aug 23
4
JOHN B HENNEMAN III
24 Aug 23
4
Richard Peters
24 Aug 23